Rad Biomed Incubator Heraklion Final Sept 18

Loading...

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

0 comments

Post a comment

    Post a comment
    Embed Video
    Edit your comment Cancel

    Favorites, Groups & Events

    Rad Biomed Incubator Heraklion Final Sept 18 - Presentation Transcript

    1. RAD Biomed Incubator The Israeli incubator program started in 1991 to provide a sheltered environment for scientists and entrepreneurs from the former USSR RBM was established in 1992 as general incubator, refocused in 1998 to biotech Located in Tel-Aviv Owned by the RAD group of companies Six active graduate companies MaimoniDex RA InnoScent Ltd
    2. The RAD Biomed Portfolio 9 Incubator companies ARIO MEDICA Gene therapy Peripheral atherectomy Drug-delivery pump Improved enzymes Molecular diagnostics Cord-blood harvesting TouchMed OccuPharma TissueDetect Endoscopy Opthalmic drug-delivery Epidural-space detection
    3. Our Philosophy RBM is a biotech incubator that serves as a natural interface between the world of Israeli academic research and the global biotech industry Long term vision: to build viable businesses and to create sustainable benefits to the economy and a significant return to investors and to the entrepreneurs The goal of the incubation period is to prove the technological concept and its feasibility and to advance it towards commercialization. To attain our goal we establish for each project a business model & strong IP position, and demonstrate that it can attain profitability in a targeted market segment
    4. The Deal Flow Projects are admitted to RBM either as a concept or as a small team with molecule/technology & executive-summary/IP/work-plan etc. Deal flow is generated in the following manner: Entrepreneurs approach the incubator Via our working relationship with TTOs Proactive search for projects in Israeli academia and hospitals Personal contacts
    5. Screening the deal-Flow Rad BioMed Functions as a mini Pre-Seed VC Incoming Test Criteria deal- flow • Clinical Need • Team Product RAD BioMed’s • Market Positioning Investment • IP Proactive Committee • Technology search • Project status for projects Approval
    6. Nurturing The Young Project Our Nurturing Approach: Mapping the needs (to reach the long-term goal), Assessing all the available resources at set-up, Implementing and supporting While keeping our focus on the startup’s long term goals, we build the company’s work-plan & activities step- by-step to position it for the next round of financing RBM provides the incubator projects : • Management & legal and financial support • Business development and clinical consulting IP strategy and regulatory & reimbursement planning • • Extensive lab space for R&D
    7. Nurturing The People In an ideal world, the “unskilled” entrepreneur would step aside and make room for a “seasoned” business-oriented project-leader In the “real world” we are limited by budget constraints, so we appoint a project manager and then mentor and coach … Coaching, coaching, coaching: coaching Active interaction with project managers Creating a “business-oriented” thinking process Adhering to work-plan
    8. Funding RBM incubator is owned and funded by the Chairman of the RAD Group of Companies The projects are funded by the Israeli Government and matching-funds are provided by the owner of RBM Additional funding may be provided by business angels before or upon entry, and/or during the incubation period Our companies seek VC or corporate funding upon graduation and at-times also during the incubation period RBM maintains an active role in the fundraising process
    9. Task Oriented Management Team Idan Tamir, Ph.D. President & CEO Binah Baum, Ph.D. MBA Shoshi Keynan, Ph.D. Director, Business Dev Project Manager Clinical & regulatory project IP experts experts Medical device Drug development consultants specialists RAD group of companies
    10. Handling The Maturing Company Building Value To The Next Level √ Demonstrating proof of concept –critical milestone √ Creating a strong IP position with freedom to operate √ Initiating regulatory procedures – what does the FDA look for? Initiating discussion with regulatory consultants √ Preparing succinct business plan for next investment round √ Creating a professional advisory board & appointing a medical director √ Initiating alliances with companies e.g. FP7 consortia √ Helping to secure follow-up financing / alliances with strategic partners
    11. Is project funding sufficient for required tasks? Weaknesses will the tight budget allow us to chose the “perfect” manager? How well do Government financing programs adapt to changing needs? Distance from global markets Support & coaching to company management Responsibility and accountability Strengths Focus on value creation - always market oriented Work-plan within a limited budget Achieving technological POC within these constraints Determination, flexibility & success orientation
    12. What do we need to do in order “to do better” ? Go Europe: create alliances Inclusion of our SMEs in FP7 consortia Participation of incubator in FP7 consortia Collaborations betw. our SMEs and clinical-centers /SMEs in other European bioregions Incubation of European pre-seed projects in RBM

    + ignatiadisignatiadis, 3 years ago

    custom

    304 views, 0 favs, 0 embeds more stats

    More info about this document

    © All Rights Reserved

    Go to text version

    • Total Views 304
      • 304 on SlideShare
      • 0 from embeds
    • Comments 0
    • Favorites 0
    • Downloads 5
    Most viewed embeds

    more

    All embeds

    less

    Flagged as inappropriate Flag as inappropriate
    Flag as inappropriate

    Select your reason for flagging this presentation as inappropriate. If needed, use the feedback form to let us know more details.

    Cancel
    File a copyright complaint
    Having problems? Go to our helpdesk?

    Categories